These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21657808)

  • 1. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA; Kamal KM; Pawar G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain.
    Dembek C; White LA; Quach J; Szkurhan A; Rashid N; Blasco MR
    Eur J Health Econ; 2014 May; 15(4):353-62. PubMed ID: 23615954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.
    Zhang X; Hay JW; Niu X
    CNS Drugs; 2015 Jan; 29(1):71-81. PubMed ID: 25326785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
    Palace J; Duddy M; Bregenzer T; Lawton M; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Dobson C
    Lancet Neurol; 2015 May; 14(5):497-505. PubMed ID: 25841667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.
    Janković SM; Kostić M; Radosavljević M; Tesić D; Stefanović-Stoimenov N; Stevanović I; Raković S; Aleksić J; Folić M; Aleksić A; Mihajlović I; Biorac N; Borlja J; Vucković R
    Vojnosanit Pregl; 2009 Jul; 66(7):556-62. PubMed ID: 19678581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.
    Einarson TR; Bereza BG; Machado M
    Curr Med Res Opin; 2017 Mar; 33(3):579-593. PubMed ID: 28027680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.